用小分子抑制剂向MAO-B:抗癌研究十年的进展 (2012-2024)
Iyman Alsaad1, Diana M A Abdel Rahman1, Ola Al-Tamimi1
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan.
Molecules (Basel, Switzerland)
|January 11, 2025
概括
单胺氧化酶B (MAO-B) 的过度表达通过增加反应性氧物种来促进癌症. 抑制MAO-B通过阻碍瘤生长和诱导亡,显示出癌症治疗的前景.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 单氨基氧化酶B (MAO-B) 对于生物氨基代谢至关重要.
- 过度表达MAO-B与各种癌症有关 (质母细胞瘤,结直肠,肺,脏,膀).
- MAO-B通过反应性氧物种 (ROS) 生产为癌症病原体做出贡献.
研究的目的:
- 在癌症中审查MAO-B网络生物学.
- 分析MAO-B联体结合和分子建模.
- 讨论MAO-B抑制剂作为潜在的抗癌药物.
主要方法:
- 对MAO-B抑制剂 (2012-2024) 的文献综述.
- 网络生物学分析将MAO-B与糖解路径联系起来.
- 对MAO-B连接体相互作用的分子建模.
主要成果:
- 已确定糖解路径是MAO-B与癌症之间的关键联系.
- 分子建模揭示了一个含有关键残留物 (Tyr398,Tyr435) 的疏水性结合口袋.
- 各种MAO-B抑制剂支架在临床前癌症模型中显示出潜力.
结论:
- 抑制MAO-B会阻碍癌细胞的增殖,并诱导细胞亡.
- MAO-B 抑制剂对于各种恶性瘤来说是一个有前途的治疗策略.
- 需要进一步的研究来优化MAO-B抑制剂的疗效和特异性.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Electron Transport Chain: Complex I and II
11.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.1K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


